Skip main navigation
International Stroke Conference Moderated Poster Abstracts
Session Title: Acute Endovascular Treatment Moderated Poster Tour

Abstract W MP9: Preliminary Results from the Survival and Outcome After Stroke (SOS) Trial: Natural History of Acute Ischemic Stroke from Large Vessel Occlusion

Originally published 2015;46:AWMP9

    Purpose: Limited literature is available on the natural history of the stroke cohort eligible for mechanical thrombectomy. Reported herein are data in a stroke cohort eligible for but untreated by mechanical thrombectomy and ineligible or refractory to IV rtPA. The goal of this study (SOS) is to obtain the natural demographics and functional outcome of patients with acute ischemic stroke from large vessel thromboembolism.

    Methods: The SOS Trial is a prospective, single-arm, multicenter study based in the United Kingdom and Germany. Patients can be enrolled presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset from a large vessel occlusion and a NIHSS of at least 10. The primary endpoint is functional outcome at 90 days as defined by mRS of 0-2. Interim data was collected and analyzed. The secondary endpoints include good neurological outcome as defined by an NIHSS score of 0-1 or a 10 points or more improvement in this scale at discharge, all cause mortality, and the incidence of hemorrhage.

    Results: To date, 137 patients were enrolled at 16 centers. Data was available for 42/137 (30.7%) patients. The mean age was 62.4+21.2; median admission NIHSS was 18 (10-31). Occlusions were in the MCA (71.4%), ICA (21.4%), ACA (4.8%), and other (2.4%). Good 90-day outcome was achieved in 13.9% (5/36); 15.0% (6/40) died. The serious adverse event rate was 24.4 (32/131). A total of 7 (17.1%) patients suffered intracerebral hemorrhage. Good neurological outcome rate was 14.7% (5/34).

    Conclusion: Preliminary data showed that large vessel acute ischemic stroke leads to poor patient outcomes if untreated. With further data collected from the remaining patients enrolled, this can help advance our knowledge of the natural course of stroke and serve as a benchmark for future endovascular trials.


    Author Disclosures: I.Q. Grunwald: None. M. Sneade: None. A. Clarke: None. J. Yarnold: None. E. Warburton: None. S. Nagel: None. P. Guyler: None. K. Fassbender: None. C. Roffe: None. R. Chapot: None. D. Briley: None. A. Dixit: None. F. Harrington: None. R. Perry: None. P. Bath: None. C. Douglass: None. D. Mangion: None. D. Manawadu: None. B. Monyham: None. B. Bock: None. L. Ammar: None. H. Buell: None. A. Boose: None. S. Sit: None.


    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.